China Pharma Holdings (CPHI) Operating Leases (2019 - 2026)

China Pharma Holdings has reported Operating Leases for 8 years, with the latest figure at $92294.0 in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases changed N/A year-over-year to $92294.0; the trailing twelve-month figure through Mar 2026 stood at $92294.0 (changed N/A YoY), and the FY2025 full-year result was $111548.0, up 183.67% from the prior year.
• Operating Leases for Q1 2026 stood at $92294.0, down from $111548.0 in the prior quarter.
• The five-year high for Operating Leases was $198583.0 in Q3 2025, with the low at $20008.0 in Q1 2024.
• Historically, Operating Leases has averaged $73091.2 across 5 years, with a median of $59163.0 in 2022.
• Annual changes were most pronounced in 2022 — Operating Leases surged 307.55% — and 2023, when it sank 81.08%.
• China Pharma Holdings' Operating Leases stood at $40445.0 in 2022, then declined by 1.32% to $39910.0 in 2023, then decreased by 1.47% to $39323.0 in 2024, then jumped by 183.67% to $111548.0 in 2025, then slipped by 17.26% to $92294.0 in 2026.
• The last three Operating Leases figures came in at $92294.0 (Q1 2026), $111548.0 (Q4 2025), and $198583.0 (Q3 2025), per Business Quant data.